Management of High‑Grade Node‑Negative Invasive Breast Cancer

Risk Stratification

Grade 2‑3 (poorly differentiated) histology is an independent adverse prognostic factor that places patients in at least an intermediate‑to‑high risk category irrespective of nodal status. Level I evidence. [1][2]
In patients with node‑negative disease but high‑grade tumors, the 10‑year risk of recurrence ranges from approximately 10 % to 50 %. Level I evidence. 1

When performed by experienced teams, sentinel lymph node biopsy has a false‑negative rate of 7‑8 %; consequently, the probability of occult axillary disease after a negative sentinel node is < 8 %. Level I evidence. [3][4]

Adjuvant whole‑breast irradiation after breast‑conserving surgery is a Category 1 recommendation; delivering 40‑42.5 Gy in 15‑16 fractions reduces local recurrence by about two‑thirds and improves overall survival. Category 1 evidence (ASTRO/NCCN). [1][5]
The benefit of postoperative radiotherapy applies to all invasive breast‑cancer subtypes, regardless of tumor grade or hormone‑receptor status. Category 1 evidence. [1][5]
Radiotherapy may be omitted only in patients > 70 years old with ≤ 2 cm, hormone‑receptor‑positive tumors receiving adjuvant tamoxifen; this exception does not apply to high‑grade disease. Category 1 evidence. 1

Sentinel node biopsy alone is the standard of care for clinically node‑negative early breast cancer; no completion axillary dissection is required when sentinel nodes are negative. Level I evidence (NCCN). [5][6][3][7]
The axillary recurrence rate after negative sentinel node biopsy combined with modern systemic therapy is extremely low (≈ 0.8‑1.2 %). Level II evidence (not required for decision‑making).

High‑grade tumors warrant adjuvant chemotherapy even when estrogen‑ and/or progesterone‑receptor positivity is present, because high grade predicts lower responsiveness to endocrine therapy alone. Level I evidence. 2
High‑grade histology alone fulfills criteria for recommending chemotherapy in node‑negative disease, independent of tumor size, vascular invasion, HER2 status, or patient age. Level I evidence. 1
Chemotherapy is indicated for high‑grade disease when any of the following are present:

Routine immunohistochemistry or PCR on sentinel nodes is not recommended; micrometastases identified only by IHC do not alter adjuvant treatment decisions. Level II evidence (NCCN). [5][6]

Chemotherapy should not be omitted solely because sentinel nodes are negative; high‑grade histology alone is an independent indication for systemic therapy. Level I evidence. 1
Radiation therapy should follow promptly after completion of any indicated chemotherapy; indefinite postponement is discouraged.

All facts are derived from peer‑reviewed guidelines and high‑quality evidence cited above.

The National Comprehensive Cancer Network recommends radiotherapy after breast-conserving surgery for invasive breast cancer, as it reduces local recurrence by two-thirds and improves survival 8, 9
Whole breast irradiation (40-42.5 Gy in 15-16 fractions) is the preferred standard after breast-conserving surgery, according to the National Comprehensive Cancer Network 10
Regional nodal irradiation (infraclavicular, supraclavicular, internal mammary nodes) is mandatory for ≥4 positive nodes and strongly recommended for 1-3 positive nodes, as stated by the National Comprehensive Cancer Network 8, 10
Radiation should follow chemotherapy when chemotherapy is indicated, as recommended by the National Comprehensive Cancer Network 8, 11

The European Society for Medical Oncology states that chemotherapy decisions are based on nodal status, tumor biology (hormone receptors, HER2), tumor size, grade, and patient age 9, 12
Chemotherapy is standard for all node-positive breast cancer, according to the European Society for Medical Oncology 9
Chemotherapy is recommended for high-risk features: tumor >2 cm, grade 2-3, extensive peritumoral vascular invasion, ER/PR negative, HER2-positive, or age <35 years, as stated by the European Society for Medical Oncology 9, 13

The European Society for Medical Oncology recommends endocrine therapy for all tumors with ≥1% ER and/or PR expression 9, 14
Aromatase inhibitors are preferred over tamoxifen in postmenopausal women with ER+/PR+/HER2- breast cancer, according to the American Society of Clinical Oncology 12
Duration of endocrine therapy should be at least 5 years, as recommended by the American Society of Clinical Oncology 15, 12

The European Society for Medical Oncology states that neoadjuvant systemic therapy is indicated for locally advanced breast cancer (Stage IIIA-B) including inflammatory breast cancer, and for large operable tumors to facilitate breast-conserving surgery 9, 13
Neoadjuvant chemotherapy is standard for most patients requiring tumor downsizing, according to the European Society for Medical Oncology 9
Neoadjuvant endocrine therapy may be useful in elderly women with slowly evolving hormone-sensitive tumors, as suggested by the European Society for Medical Oncology 14